Get notified when SVRA files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Risk Profile Improvements

  • Debt Default (removed) — Prior quarter disclosed specific debt default and acceleration risks under Hercules Loan Agreement; current quarter contains only boilerplate reference to 10-K.
  • Covenant Violation (removed) — Prior quarter disclosed covenant compliance risks including Cash Requirement and Conditional Minimum Revenue Covenant; current quarter removed this disclosure entirely.
  • Securities Litigation (removed) — Securities class action was filed but subsequently voluntarily dismissed by plaintiffs in February 2026.
NASDAQ: SVRA Savara Inc 10-Q

FDA extends MOLBREEVI review to Nov 2026; securities suits dismissed; debt covenant risks removed

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

Key Changes

  • high

    FDA extended MOLBREEVI approval decision by three months to November 22, 2026 after determining company responses to information requests constituted a major BLA amendment, delaying potential commercialization and revenue generation.

    MD&A: FDA BLA Review verify on EDGAR →
  • high

    EMA validated European marketing application (decision expected Q1 2027) and UK MHRA granted accelerated 150-day review (decision expected Q4 2026), opening two additional regulatory pathways beyond the FDA.

    MD&A: International Regulatory Progress verify on EDGAR →
  • high

    Q1 2026 net loss jumped 40% to $37.3M from $26.6M year-ago, driven by $6.0M stock compensation increase and $2.5M CMC manufacturing scale-up, while cash position improved to $202.8M from $172.5M on 2025 equity raises.

    MD&A: Financial Performance verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.

Partner

Trade SVRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify